Matricellular proteins in immunometabolism and tissue homeostasis

키워드

참고문헌 (206)

1. Murphy-Ullrich JE, "Revisiting the matricellular concept", Matrix Biol, 37, pp.1~14 (2014)
2. Bornstein P, "Matricellular proteins : extracellular modulators of cell function", Curr Opin Cell Biol, 14, pp.608~616 (2002)
3. Bornstein P, "Diversity of function is inherent in matricellular proteins : an appraisal of thrombospondin 1", J Cell Biol, 130, pp.503~506 (1995)
4. Chiodoni C, "Matricellular proteins : from homeostasis to inflammation, cancer, and metastasis", Cancer Metastasis Rev, 29, pp.295~307 (2010)
5. O’Neill LAJ, "A guide to immunometabolism for immunologists", Nat Rev Immunol, 16, pp.553~565 (2016)
6. Hotamisligil GS, "Inflammation and metabolic disorders", Nature, 444, pp.860~867 (2006)
7. Schellings MWM, "Absence of SPARC results in increased cardiac rupture and dysfunction after acute myocardial infarction", J Exp Med, 206, pp.113~123 (2008)
8. Kiefer FW, "Neutralization of osteopontin inhibits obesity-induced inflammation and insulin resistance", Diabetes, 59, pp.935~946 (2010)
9. Kuijpers MJE, "Supporting roles of platelet thrombospondin-1 and CD36 in thrombus formation on collagen", Arterioscler Thromb Vasc Biol, 34, pp.1187~1192 (2014)
10. Phelan MW, "Hypoxia increases thrombospondin-1 transcript and protein in cultured endothelial cells", J Lab Clin Med, 132, pp.519~529 (1998)
11. DiPietro LA, "Thrombospondin 1 synthesis and function in wound repair", Am J Pathol, 148, pp.1851~1860 (1996)
12. Kyriakides TR, "Accelerated wound healing in mice with a disruption of the thrombospondin 2 gene", J Invest Dermatol, 113, pp.782~787 (1999)
13. Nakagawa T, "TGF- induces proangiogenic and antiangiogenic factorsvia parallel but distinct Smad pathways", Kidney Int, 66, pp.605~613 (2004)
14. Morgan-Rowe L, "Thrombospondin 1 in hypoxia-conditioned media blocks the growth of human microvascular endothelial cells and is increased in systemic sclerosis tissues", Fibrogenesis Tissue Repair, 4, pp.13~ (2011)
15. Bae ON, "Oxidative stress-mediated thrombospondin-2 upregulation impairs bone marrow-derived angiogenic cell function in diabetes mellitus", Arterioscler Thromb Vasc Biol, 33, pp.1920~1927 (2013)
16. Jiménez B, "Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1", Nat Med, 6, pp.41~48 (2000)
17. Chandrasekaran L, "Cell contactdependent activation of 31 integrin modulates endothelial cell responses to thrombospondin-1", Mol Biol Cell, 11, pp.2885~2900 (2000)
18. Gao AG, "Thrombospondin modulates alpha v beta 3function through integrin-associated protein", J Cell Biol, 135, pp.533~544 (1996)
19. Nunes SS, "Syndecan-4 contributes to endothelial tubulogenesis through interactions with two motifs inside the pro-angiogenic N-terminal domain of thrombospondin-1", J Cell Physiol, 214, pp.828~837 (2008)
20. Crawford SE, "Thrombospondin-1 is a major activator of TGF-1in vivo", Cell, 93, pp.1159~1170 (1998)
21. Adams JC, "The thrombospondins", Cold Spring Harbor Perspect Biol, 3, pp.a009712~a009712 (2011)
22. Gao AG, "Integrin-associated protein is a receptor for the C-terminal domain of thrombospondin", J Biol Chem, 271, pp.21~24 (1996)
23. Qian X, "Thrombospondin-1 modulates angiogenesisin vitroby up-regulation of matrix metalloproteinase-9 in endothelial cells", Exp Cell Res, 235, pp.403~412 (1997)
24. Calabro NE, "Thrombospondin-2 and extracellular matrix assembly", Biochim Biophys Acta Gen Subj, 1840, pp.2396~2402 (2014)
25. Amend SR, "Thrombospondin-1 regulates bone homeostasis through effects on bone matrix integrity and nitric oxide signaling in osteoclasts", J Bone Miner Res, 30, pp.106~115 (2015)
26. Oskarsson T, "Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs", Nat Med, 17, pp.867~874 (2011)
27. Joester A, "The structure and function of tenascins in the nervous system", Matrix Biol, 20, pp.13~22 (2001)
28. Apostolova I, "Tenascin-R restricts posttraumatic remodeling of motoneuron innervation and functional recovery after spinal cord injury in adult mice", J Neurosci, 26, pp.7849~7859 (2006)
29. Sakai T, "Tenascin-X expression in tumor cells and fibroblasts : glucocorticoids as negative regulators in fibroblasts", J Cell Sci, 109, pp.2069~2077 (1996)
30. Martina E, "Tenascin-W is a specific marker of glioma-associated blood vessels and stimulates angiogenesis in vitro", FASEB J, 24, pp.778~787 (2010)
31. Berking C, "Transforming growth factor-1 increases survival of human melanoma through stroma remodeling1", Cancer Res, 61, pp.8306~8316 (2001)
32. Nakamura Y, "Ets-1 regulates TNF--induced matrix metalloproteinase-9 and tenascin expression in primary bronchial fibroblasts1", J Immunol, 172, pp.1945~1952 (2004)
33. Chiquet M, "From mechanotransduction to extracellular matrix gene expression in fibroblasts", Biochim Biophys Acta Mol Cell Res, 1793, pp.911~920 (2009)
34. Derr LB, "The distribution of tenascin-R in the developing avian nervous system", J Exp Zool, 280, pp.152~164 (1998)
35. Takeda K, "Brain-derived neurotrophic factor enhances periodontal tissue regeneration", Tissue Eng, 11, pp.1618~1629 (2005)
36. Scherberich A, "Tenascin-W is found in malignant mammary tumors, promotes alpha8integrin-dependent motility and requires p38MAPK activity for BMP-2 and TNF-alpha induced expression in vitro", Oncogene, 24, pp.1525~1532 (2005)
37. Huang W, "Interference of tenascin-C with syndecan-4 binding to fibronectin blocks cell adhesion and stimulates tumor cell proliferation1", 61, pp.8586~8594 (2001)
38. Midwood KS, "Coregulation of fibronectin signaling and matrix contraction by tenascin-c and syndecan-4", Mol Biol Cell, 15, pp.5670~5677 (2004)
39. Zacharias U, "Competition and cooperation between tenascin-R, lecticans and contactin 1 regulate neurite growth and morphology", J Cell Sci, 119, pp.3456~3466 (2006)
40. Elefteriou F, "Cell adhesion to tenascin-X", Eur J Biochem, 263, pp.840~848 (1999)
41. Chung CY, "Mitogenesis, cell migration, and loss of focal adhesions induced by tenascin-C interacting with its cell surface receptor, annexin II", Mol Biol Cell, 7, pp.883~892 (1996)
42. Nishio T, "Tenascin-C regulates proliferation and migration of cultured astrocytes in a scratch wound assay", Neuroscience, 132, pp.87~102 (2005)
43. Sun Z, "Tenascin-C promotes tumor cell migration and metastasis through integrin 91-mediated YAP inhibition", Cancer Res, 78, pp.950~961 (2018)
44. Faissner A, "Tenascin-C in the matrisome of neural stem and progenitor cells", Mol Cell Neurosci, 81, pp.22~31 (2017)
45. Imanaka-Yoshida K, "Tenascin-C and mechanotransduction in the development and diseases of cardiovascular system", Front Physiol, 5, pp.283~ (2014)
46. Elefteriou F, "Binding of tenascin-X to decorin", FEBS Lett, 495, pp.44~47 (2001)
47. Yamate T, "Osteopontin expression by osteoclast and osteoblast progenitors in the murine bone marrow : demonstration of its requirement for osteoclastogenesis and its increase after ovariectomy", Endocrinology, 138, pp.3047~3055 (1997)
48. Ashkar S, "Eta-1(osteopontin) : an early component of type-1(cellmediated)immunity", Science, 287, pp.860~864 (2000)
49. Shinohara ML, "Osteopontin expression is essential for interferon- production by plasmacytoid dendritic cells", Nat Immunol, 7, pp.498~506 (2006)
50. Mori R, "Molecular mechanisms linking wound inflammation and fibrosis : knockdown of osteopontin leads to rapid repair and reduced scarring", J Exp Med, 205, pp.43~51 (2008)
51. Zhao H, "The role of osteopontin in the progression of solid organ tumour", Cell Death Dis, 9, pp.356~ (2018)
52. Schulz G, "Regulated osteopontin expression by dendritic cells decisively affects their migratory capacity", J Invest Dermatol, 128, pp.2541~2544 (2008)
53. Prince CW, "1, 25-Dihydroxyvitamin D3 regulates the biosynthesis of osteopontin, a bone-derived cell attachment protein, in clonal osteoblast-like osteosarcoma cells", Coll Relat Res, 7, pp.305~313 (1987)
54. Hullinger TG, "TGF and BMP-2 activation of the OPN promoter : roles of smad-and hox-binding elements", Exp Cell Res, 262, pp.69~74 (2001)
55. Maeda N, "Osteopontin-integrin interaction as a novel molecular target for antibody-mediated immunotherapy in adult T-cell leukemia", Retrovirology, 12, pp.99~ (2015)
56. Katagiri YU, "CD44variants but not CD44s cooperate with 1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis1", Cancer Res, 59, pp.219~226 (1999)
57. Kläning E, "Osteopontin binds multiple calcium ions with high affinity and independently of phosphorylation status", Bone, 66, pp.90~95 (2014)
58. Senger DR, "Adhesive properties of osteopontin : regulation by a naturally occurring thrombin-cleavage in close proximity to the GRGDS cell-binding domain", Mol Biol Cell, 5, pp.565~574 (1994)
59. Chellaiah MA, "The integrin alpha(v)beta(3)and CD44 regulate the actions of osteopontin on osteoclast motility", Calcif Tissue Int, 72, pp.197~205 (2003)
60. Zhang H, "Osteopontin knockdown inhibits v, 3 integrin-induced cell migration and invasion and promotes apoptosis of breast cancer cells by inducing autophagy and inactivating the PI3K", Akt, Cell Physiol Biochem, pp.2014, 33[DOI]
61. Zhu B, "Osteopontin modulates CD44-dependent chemotaxis of peritoneal macrophages through G-protein-coupled receptors : evidence of a role for an intracellular form of osteopontin", J Cell Physiol, 198, pp.155~167 (2004)
62. Liu J, "Osteopontin promotes the progression of gastric cancer through the NF-B pathway regulated by the MAPK and PI3K", Int J Oncol, 45, pp.282~290 (2014)
63. Weber GF, "Receptor-ligand interaction between CD44 and osteopontin(Eta-1)", Science, 271, pp.509~512 (1996)
64. Ge Q, "Osteopontin regulates macrophage activation and osteoclast formation in hypertensive patients with vascular calcification", Sci Rep, 7, pp.40253~ (2017)
65. Moreno-Viedma V, "Osteopontin-deficient progenitor cells display enhanced differentiation to adipocytes", Obes Res Clin Pract, 12, pp.277~285 (2018)
66. Bradshaw AD, "The role of SPARC in extracellular matrix assembly", J Cell Commun Signaling, 3, pp.239~246 (2009)
67. Termine JD, "Osteonectin, a bone-specific protein linking mineral to collagen", Cell, 26, pp.99~105 (1981)
68. Arnold SA, "SPARC : a matricellular regulator of tumorigenesis", J Cell Commun Signaling, 3, pp.255~273 (2009)
69. Gan KJ, "SPARCL1 promotes excitatory but not inhibitory synapse formation and function independent of neurexins and neuroligins", J Neurosci, 40, pp.8088~8102 (2020)
70. Reed MJ, "TGF-1 induces the expression of type I collagen and SPARC, and enhances contraction of collagen gels, by fibroblasts from young and aged donors", J Cell Physiol, 158, pp.169~179 (1994)
71. Kato Y, "Induction of SPARC by VEGF in human vascular endothelial cells", Biochem Biophys Res Commun, 287, pp.422~426 (2001)
72. McKinnon PJ, "SC1 : a marker for astrocytes in the adult rodent brain is upregulated during reactive astrocytosis", Brain Res, 709, pp.27~36 (1996)
73. Shin M, "Exogenous SPARC suppresses proliferation and migration of prostate cancer by interacting with integrin 1", Prostate, 73, pp.1159~1170 (2013)
74. Kupprion C, "SPARC(BM-40, Osteonectin)inhibits the mitogenic effect of vascular endothelial growth factor on microvascular endothelial cells", J Biol Chem, 273, pp.29635~29640 (1998)
75. Sullivan MM, "Matricellular hevin regulates decorin production and collagen assembly", J Biol Chem, 281, pp.27621~27632 (2006)
76. Martinek N, "Haemocyte-derived SPARC is required for collagen-IV-dependent stability of basal laminae in Drosophila embryos", J Cell Sci, 121, pp.1671~1680 (2008)
77. Wang H, "Secreted protein acidic and rich in cysteine(SPARC", osteonectin, Matrix Biol, pp.2006, 25[DOI]
78. Girard JP, "Modulation of endothelial cell adhesion by hevin, an acidic protein associated with high endothelial venules", J Biol Chem, 271, pp.4511~4517 (1996)
79. McClung HM, "SPARC upregulates MT1-MMP expression, MMP-2 activation, and the secretion and cleavage of galectin-3 in U87MG glioma cells", Neurosci Lett, 419, pp.172~177 (2007)
80. Wang Y, "SPARCL1influences bovine skeletal muscle-derived satellite cell migration and differentiation through an ITGB1-mediated signaling pathway", Animals, 10, pp.1361~ (2020)
81. Delany AM, "Osteopenia and decreased bone formation in osteonectin-deficient mice", J Clin Invest, 105, pp.915~923 (2000)
82. Perbal B, "CCN proteins : a centralized communication network", J Cell Commun Signal, 7, pp.169~177 (2013)
83. Hutchenreuther J, "Cancer-associated fibroblast-specific expression of the matricellular protein CCN1 coordinates neovascularization and stroma deposition in melanoma metastasis", Cancer Res Commun, 4, pp.556~570 (2024)
84. Lee S, "Interplay between CCN1 and Wnt5a in endothelial cells and pericytes determines the angiogenic outcome in a model of ischemic retinopathy", Sci Rep, 7, pp.1405~ (2017)
85. Takigawa M, "CCN2 : a master regulator of the genesis of bone and cartilage", J Cell Commun Signal, 7, pp.191~201 (2013)
86. Kaasbøll OJ, "Connective tissue growth factor(CCN2)is a matricellular preproprotein controlled by proteolytic activation", J Biol Chem, 293, pp.17953~17970 (2018)
87. Hall-Glenn F, "CCN2", connective tissue growth factor is essential for pericyte adhesion and endothelial basement membrane formation during angiogenesis, 2012, pp.7, e30562~
88. Ellis PD, "Nov gene encodes adhesion factor for vascular smooth muscle cells and is dynamically regulated in response to vascular injury", Arterioscler Thromb Vasc Biol, 20, pp.1912~1919 (2000)
89. Son S, "CCN3", NOV promotes metastasis and tumor progression via GPNMB-induced EGFR activation in triple-negative breast cancer, 2023, pp.14, 81~
90. Giusti V, "CCN proteins in the musculoskeletal system : current understanding and challenges in physiology and pathology", J Cell Commun Signal, 15, pp.545~566 (2021)
91. Banerjee S, "CCN5", WISP-2expression in breast adenocarcinoma is associated with less frequent progression of the disease and suppresses the invasive phenotypes of tumor cells, 2008, pp.68, 7606~7612
92. Pennica D, "WISP genes are members of the connective tissue growth factor family that are up-regulated in Wnt-1-transformed cells and aberrantly expressed in human colon tumors", Proc Natl Acad Sci U S A, 95, pp.14717~14722 (1998)
93. Zhang F, "The matricellular protein Cyr61 is a key mediator of platelet-derived growth factor-induced cell migration", J Biol Chem, 290, pp.8232~8242 (2015)
94. Athanasopoulos AN, "Vascular endothelial growth factor(VEGF)-induced Upregulation of CCN1 in osteoblasts mediates proangiogenic activities in endothelial cells and promotes fracture healing", J Biol Chem, 282, pp.26746~26753 (2007)
95. Grotendorst GR, "A novel transforming growth factor beta response element controls the expression of the connective tissue growth factor gene", Cell Growth Differ, 7, pp.469~480 (1996)
96. van Roeyen CRC, "CCN3 is a novel endogenous PDGF-regulated inhibitor of glomerular cell proliferation", Kidney Int, 73, pp.86~94 (2008)
97. Liu Y, "The emerging role of WISP proteins in tumorigenesis and cancer therapy", J Transl Med, 17, pp.28~ (2019)
98. Leu SJ, "Pro-angiogenic activities of CYR61(CCN1)mediated through Integrins v3 and 61 in human umbilical vein endothelial cells", J Biol Chem, 277, pp.46248~46255 (2002)
99. Inoki I, "Connective tissue growth factor binds vascular endothelial growth factor(VEGF)and inhibits VEGF-induced angiogenesis", FASEB J, 16, pp.1~27 (2002)
100. Gao R, "Connective tissue growth factor(CCN2)induces adhesion of rat activated hepatic stellate cells by binding of its C-terminal domain to integrin v3 and heparan sulfate proteoglycan", J Biol Chem, 279, pp.8848~8855 (2004)
101. Lin CG, "CCN3(NOV)Is a novel angiogenic regulator of the CCN protein family", J Biol Chem, 278, pp.24200~24208 (2003)
102. Desnoyers L, "WISP-1binds to decorin and biglycan", J Biol Chem, 276, pp.47599~47607 (2001)
103. Myers RB, "The matricellular protein CCN5 regulates podosome function via interaction with integrin v3", J Cell Commun Signal, 8, pp.135~146 (2014)
104. Chen CC, "The angiogenic factors Cyr61 and connective tissue growth factor induce adhesive signaling in primary human skin fibroblasts", J Biol Chem, 276, pp.10443~10452 (2001)
105. Kiwanuka E, "CCN2 promotes keratinocyte adhesion and migration via integrin 51", Exp Cell Res, 319, pp.2938~2946 (2013)
106. Ivkovic S, "Connective tissue growth factor coordinates chondrogenesis and angiogenesis during skeletal development", Development, 130, pp.2779~2791 (2003)
107. Safadi FF, "Expression of connective tissue growth factor in bone : its role in osteoblast proliferation and differentiation in vitro and bone formation in vivo", J Cell Physiol, 196, pp.51~62 (2003)
108. de Vega S, "TM14 is a new member of the fibulin family(fibulin-7)that interacts with extracellular matrix molecules and is active for cell binding", J Biol Chem, 282, pp.30878~30888 (2007)
109. Godyna S, "Fibulin-1 mediates platelet adhesion via a bridge of fibrinogen", Blood, 88, pp.2569~2577 (1996)
110. Ibrahim AM, "Fibulin-2is required for basement membrane integrity of mammary epithelium", Sci Rep, 8, pp.14139~ (2018)
111. Tsuda T, "Fibulin-2expression marks transformed mesenchymal cells in developing cardiac valves, aortic arch vessels, and coronary vessels", Dev Dynam, 222, pp.89~100 (2001)
112. McLaughlin PJ, "Lack of fibulin-3 causes early aging and herniation, but not macular degeneration in mice", Hum Mol Genet, 16, pp.3059~3070 (2007)
113. Kowal RC, "EVEC, a novel epidermal growth factor-like repeatcontaining protein upregulated in embryonic and diseased adult vasculature", Circ Res, 84, pp.1166~1176 (1999)
114. Ramnath NWM, "Fibulin-4 deficiency increases TGF- signalling in aortic smooth muscle cells due to elevated TGF-2levels", Sci Rep, 5, pp.16872~ (2015)
115. Chowdhury A, "Expression of fibulin-6 in failing hearts and its role for cardiac fibroblast migration", Cardiovasc Res, 103, pp.509~520 (2014)
116. Chakraborty P, "The role of adhesion protein fibulin7 in development and diseases", Mol Med, 26, pp.47~ (2020)
117. Chen L, "Differential regulation of extracellular matrix and soluble fibulin-1 levels by TGF-1 in airway smooth muscle cells", PLoS One, 8, pp.e65544~ (2013)
118. Zhang H, "Fibulin-2 deficiency attenuates angiotensin II-induced cardiac hypertrophy by reducing transforming growth factor- signalling", Clin Sci, 126, pp.275~288 (2013)
119. Hu B, "Fibulin-3 is uniquely upregulated in malignant gliomas and promotes tumor cell motility and invasion", Mol Cancer Res, 7, pp.1756~1770 (2009)
120. Murtha LA, "Fibulin-3 is necessary to prevent cardiac rupture following myocardial infarction", Sci Rep, 13, pp.14995~ (2023)
121. Gallagher WM, "Human fibulin-4 : analysis of its biosynthetic processing and mRNA expression in normal and tumour tissues", FEBS Lett, 489, pp.59~66 (2001)
122. Guadall A, "Fibulin-5 is up-regulated by hypoxia in endothelial cells through a hypoxia-inducible factor-1(HIF-1)-dependent mechanism", J Biol Chem, 286, pp.7093~7103 (2011)
123. de Vega S, "Fibulin-7 is overexpressed in glioblastomas and modulates glioblastoma neovascularization through interaction with angiopoietin-1", Int J Cancer, 145, pp.2157~2169 (2019)
124. Tran H, "The self-association and fibronectin-binding sites of fibulin-1map to calcium-binding epidermal growth factor-like domains", J Biol Chem, 272, pp.22600~22606 (1997)
125. Olin AI, "The proteoglycans aggrecan and versican form networks with fibulin-2 through their lectin domain binding", J Biol Chem, 276, pp.1253~1261 (2001)
126. Reinhardt DP, "Fibrillin-1 and fibulin-2 interact and are colocalized in some tissues", J Biol Chem, 271, pp.19489~19496 (1996)
127. Kobayashi N, "A comparative analysis of the fibulin protein family : biochemical characterization, binding interactions, and tissue localization", J Biol Chem, 282, pp.11805~11816 (2007)
128. Papke CL, "Fibulin-4 and fibulin-5 in elastogenesis and beyond : insights from mouse and human studies", Matrix Biol, 37, pp.142~149 (2014)
129. Yanagisawa H, "Fibulin-5, an integrin-binding matricellular protein : its function in development and disease", J Cell Comm Signal, 3, pp.337~347 (2009)
130. Zhang JL, "Vertebrate extracellular matrix protein hemicentin-1 interacts physically and genetically with basement membrane protein nidogen-2", Matrix Biol, 112, pp.132~154 (2022)
131. Albig AR, "Fibulins 3and 5 antagonize tumor angiogenesis in vivo", Cancer Res, 66, pp.2621~2629 (2006)
132. Cooley MA, "Fibulin-1 is required for morphogenesis of neural crest-derived structures", Dev Biol, 319, pp.336~345 (2008)
133. Horiguchi M, "Fibulin-4 conducts proper elastogenesis via interaction with cross-linking enzyme lysyl oxidase", Proc Natl Acad Sci U S A, 106, pp.19029~19034 (2009)
134. Stein EV, "Secreted thrombospondin-1 regulates macrophage interleukin-1 production and activation through CD47", Sci Rep, 6, pp.19684~ (2016)
135. Kong P, "Thrombospondin-1regulates adiposity and metabolic dysfunction in dietinduced obesity enhancing adipose inflammation and stimulating adipocyte proliferation", Am J Physiol Endocrinol Metab, 305, pp.E439~E450 (2013)
136. Shitaye HS, "Thrombospondin-2 is an endogenous adipocyte inhibitor", Matrix Biol, 29, pp.549~556 (2010)
137. Manna PP, "The mechanism of CD47-dependent killing of t cells : heterotrimeric Gidependent inhibition of protein kinase A1", J Immun, 170, pp.3544~3553 (2003)
138. Liu Z, "Thrombospondin-1(TSP1)contributes to the development of vascular inflammation by regulating monocytic cell motility in mouse models of abdominal aortic aneurysm", Circ Res, 117, pp.129~141 (2015)
139. Bergström SE, "A cytokine-controlled mechanism for integrated regulation of T-lymphocyte motility, adhesion and activation", Immunology, 140, pp.441~455 (2013)
140. Doyen V, "Thrombospondin 1 is an autocrine negative regulator of human dendritic cell activation", J Exp Med, 198, pp.1277~1283 (2003)
141. Catalán V, "Increased tenascin C and toll-like receptor 4 levels in visceral adipose tissue as a link between inflammation and extracellular matrix remodeling in obesity", J Clin Endocrinol Metab, 97, pp.E1880~E1889 (2012)
142. Midwood K, "Tenascin-C is an endogenous activator of Toll-like receptor 4that is essential for maintaining inflammation in arthritic joint disease", Nat Med, 15, pp.774~780 (2009)
143. Murdamoothoo D, "Tenascin-C immobilizes infiltrating T lymphocytes through CXCL12 promoting breast cancer progression", EMBO Mol Med, 13, pp.e13270~ (2021)
144. Koguchi Y, "High plasma osteopontin level and its relationship with interleukin-12-mediated type 1 T helper cell response in tuberculosis", Am J Respir Crit Care Med, 167, pp.1355~1359 (2003)
145. Weber GF, "Phosphorylation-dependent interaction of osteopontin with its receptors regulates macrophage migration and activation", J Leukoc Biol, 72, pp.752~761 (2002)
146. Nomiyama T, "Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice", J Clin Invest, 117, pp.2877~2888 (2007)
147. Zeyda M, "Osteopontin is an activator of human adipose tissue macrophages and directly affects adipocyte function", Endocrinology, 152, pp.2219~2227 (2011)
148. Ikeda T, "Osteopontin mRNA is expressed by smooth muscle-derived foam cells in human atherosclerotic lesions of the aorta", J Clin Invest, 92, pp.2814~2820 (1993)
149. Syn WK, "Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis", Hepatology, 53, pp.106~115 (2011)
150. Tartare-Deckert S, "The matricellular protein SPARC", osteonectin as a newly identified factor up-regulated in obesity, 2001, pp.276, 22231~22237
151. Kos K, "SPARC : a key player in the pathologies associated with obesity and diabetes", Nat Rev Endocrinol, 6, pp.225~235 (2010)
152. Shen Y, "SPARC is overexpressed in adipose tissues of diet-induced obese rats and causes insulin resistance in 3T3-L1 adipocytes", Acta Histochem, 116, pp.158~166 (2014)
153. Nie J, "SPARC inhibits adipogenesis by its enhancement of -catenin signaling", J Biol Chem, 284, pp.1279~1290 (2009)
154. Bradshaw AD, "SPARC-null mice exhibit increased adiposity without significant differences in overall body weight", Proc Natl Acad Sci U S A, 100, pp.6045~6050 (2003)
155. Ryu S, "The matricellular protein SPARC induces inflammatory interferonresponse in macrophages during aging", Immunity, 55, pp.1609~1626 (2022)
156. Ryu S, "Reduction of SPARC protects mice against NLRP3 inflammasome activation and obesity", J Clin Invest, 133, pp.e169173~ (2023)
157. Toba H, "Secreted protein acidic and rich in cysteine facilitates age-related cardiac inflammation and macrophage M1 polarization", Am J Physiol Cell Physiol, 308, pp.C972~C982 (2015)
158. Ju L, "CCN1 promotes hepatic steatosis and inflammation in non-alcoholic steatohepatitis", Sci Rep, 10, pp.3201~ (2020)
159. Bai T, "Matricellular protein CCN1 activates a proinflammatory genetic program in murine macrophages", J Immunol, 184, pp.3223~3232 (2010)
160. Imhof BA, "CCN1", CYR61-mediated meticulous patrolling by Ly6Clow monocytes fuels vascular inflammation, 2016, pp.113, E4847~4856
161. Tan JTM, "Connective tissue growth factor", CCN-2 is upregulated in epididymal and subcutaneous fat depots in a dietary-in-duced obesity model, 2013, pp.304, E1291~E1302
162. Spencer M, "Adipose tissue macrophages in insulin-resistant subjects are associated with collagen VI and fibrosis and demonstrate alternative activation", Am J Physiol Endocrinol Metab, 299, pp.E1016~E1027 (2010)
163. Rodrigues-Díez R, "The C-terminal module IV of connective tissue growth factor is a novel immune modulator of the Th17 response", Lab Invest, 93, pp.812~824 (2013)
164. Pakradouni J, "Plasma NOV", CCN3 levels are closely associated with obesity in patients with metabolic disorders, 2013, pp.8, e66788~
165. Martinerie C, "NOV", CCN3 : a new adipocytokine involved in obesity-associated insulin resistance, 2016, pp.65, 2502~2515
166. Akashi S, "Metabolic regulation of the CCN family genes by glycolysis in chondrocytes", J Cell Commun Signal, 12, pp.245~252 (2018)
167. Ferrand N, "WISP1", CCN4 inhibits adipocyte differentiation through repression of PPAR activity, 2017, pp.7, 1749~
168. Holmager P, "Galectin-3 and fibulin-1 in systolic heart failure-relation to glucose metabolism and left ventricular contractile reserve", BMC Cardiovasc Disord, 17, pp.22~ (2017)
169. Skov V, "Metformin, but not rosiglitazone, attenuates the increasing plasma levels of a new cardiovascular marker, fibulin-1, in patients with type 2 diabetes", Diabetes Care, 37, pp.760~766 (2014)
170. Nadler ST, "The expression of adipogenic genes is decreased in obesity and diabetes mellitus", Proc Natl Acad Sci U S A, 97, pp.11371~11376 (2000)
171. Li S, "Fibulin-2 : a potential regulator of immune dysfunction after bone trauma", Immun Inflamm Dis, 11, pp.e846~ (2023)
172. Runhaar J, "Fibulin-3 fragments are prognostic biomarkers of osteoarthritis incidence in overweight and obese women", Osteoarthr Cartil, 24, pp.672~678 (2016)
173. Lau ES, "Cardiovascular biomarkers of obesity and overlap with cardiometabolic dysfunction", J Am Heart Assoc, 10, pp.e020215~ (2021)
174. Okuyama T, "Identification of the matricellular protein Fibulin-5 as a target molecule of glucokinase-mediated calcineurin", NFAT signaling in pancreatic islets, 2017, pp.7, 2364~
175. Chu LY, "Thrombospondin-1 modulates VEGF signaling via CD36by recruiting SHP-1 to VEGFR2 complex in microvascular endothelial cells", Blood, 122, pp.1822~1832 (2013)
176. Rodríguez-Manzaneque JC, "Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor", Proc Natl Acad Sci U S A, 98, pp.12485~12490 (2001)
177. Streit M, "Thrombospondin-1 suppresses wound healing and granulation tissue formation in the skin of transgenic mice", EMBO J, 19, pp.3272~3282 (2000)
178. Kyriakides TR, "Mice that lack thrombospondin 2 display connective tissue abnormalities that are associated with disordered collagen fibrillogenesis, an increased vascular density, and a bleeding diathesis", J Cell Biol, 140, pp.419~430 (1998)
179. Hecht JT, "Mutations in exon 17B of cartilage oligomeric matrix protein(COMP)cause pseudoachondroplasia", Nat Genet, 10, pp.325~329 (1995)
180. Midwood KS, "Advances in tenascin-C biology", Cell Mol Life Sci, 68, pp.3175~3199 (2011)
181. Tamaoki M, "Tenascin-C regulates recruitment of myofibroblasts during tissue repair after myocardial injury", Am J Pathol, 167, pp.71~80 (2005)
182. Matsuda A, "Corneal wound healing in tenascin knockout mouse", Invest Ophthalmol Vis Sci, 40, pp.1071~1080 (1999)
183. Imanaka-Yoshida K, "Tenascin-C in development and disease of blood vessels", Anat Rec, 297, pp.1747~1757 (2014)
184. Zweers MC, "Haploinsufficiency of TNXB is associated with hypermobility type of ehlers-danlos syndrome", Am J Hum Genet, 73, pp.214~217 (2003)
185. Icer MA, "The multiple functions and mechanisms of osteopontin", Clin Biochem, 59, pp.17~24 (2018)
186. Ross FP, "Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alpha v beta 3potentiate bone resorption", J Biol Chem, 268, pp.9901~9907 (1993)
187. Wang W, "Osteopontin activates mesenchymal stem cells to repair skin wound", PLoS One, 12, pp.e0185346~ (2017)
188. Gao H, "Osteopontin regulates -smooth muscle actin and calponin in vascular smooth muscle cells", Cell Biol Int, 36, pp.155~161 (2012)
189. Riew TR, "Osteopontin and its spatiotemporal relationship with glial cells in the striatum of rats treated with mitochondrial toxin 3-nitropropionic acid : possible involvement in phagocytosis", J Neuroinflamm, 16, pp.99~ (2019)
190. Norose K, "SPARC deficiency leads to early-onset cataractogenesis", Invest Ophthalmol Vis Sci, 39, pp.2674~2680 (1998)
191. Rentz TJ, "SPARC regulates processing of procollagen I and collagen fibrillogenesis in dermal fibroblasts", J Biol Chem, 282, pp.22062~22071 (2007)
192. Reed MJ, "Differential expression of SPARC and thrombospondin 1 in wound repair : immunolocalization and in situ hybridization", J Histochem Cytochem, 41, pp.1467~1477 (1993)
193. Kucukdereli H, "Control of excitatory CNS synaptogenesis by astrocyte-secreted proteins Hevin and SPARC", Proc Natl Acad Sci U S A, 108, pp.E440~E449 (2011)
194. Chaurasia SS, "Hevin plays a pivotal role in corneal wound healing", PLoS One, 8, pp.e81544~ (2013)
195. Chen CC, "Functions and mechanisms of action of CCN matricellular proteins", Int J Biochem Cell Biol, 41, pp.771~783 (2009)
196. Jun JI, "The matricellular protein CCN1induces fibroblast senescence and restricts fibrosis in cutaneous wound healing", Nat Cell Biol, 12, pp.676~685 (2010)
197. Tsang M, "CCN2 is required for recruitment of Sox2-expressing cells during cutaneous tissue repair", J Cell Commun Signal, 9, pp.341~346 (2015)
198. Lin CG, "Integrin-dependent functions of the angiogenic inducer NOV(CCN3) : implication in wound healing", J Biol Chem, 280, pp.8229~8237 (2005)
199. Ono M, "CCN4", WISP1controls cutaneous wound healing by modulating proliferation, migration and ECM expression in dermal fibroblasts via 51 and TNF, 2018, pp.68, 533~546
200. Argraves WS, "Fibulin is an extracellular matrix and plasma glycoprotein with repeated domain structure", J Cell Biol, 111, pp.3155~3164 (1990)
201. Balbona K, "Fibulin binds to itself and to the carboxyl-terminal heparin-binding region of fibronectin", J Biol Chem, 267, pp.20120~20125 (1992)
202. Yasmin, "The matrix proteins aggrecan and fibulin-1 play a key role in determining aortic stiffness", Sci Rep, 8, pp.8550~ (2018)
203. Li SD, "Fibulin2 : a negative regulator of BMSC osteogenic differentiation in infected bone fracture healing", Exp Mol Med, 55, pp.443~456 (2023)
204. Lin Z, "Fibulin-3 may improve vascular health through inhibition of MMP-2", 9 and oxidative stress in spontaneously hypertensive rats, 2016, pp.13, 3805~3812
205. Gerarduzzi C, "The matrix revolution : matricellular proteins and restructuring of the cancer microenvironment", Cancer Res, 80, pp.2705~2717 (2020)
206. Prakoura N, "Matricellular proteins and organ fibrosis", Curr Pathobiol Rep, 5, pp.111~121 (2017)

관련 논문AI추천